natgillin/translations-raw huggingface dataset:
The method for producing a dermal matrix system with micro particles according to claim 1, wherein in the step of adding the laminin into the collagen solution and forming the first mixture, the collagen solution has a volume of 2.5 mL, the laminin has a volume of 20 ul, and the first mixture is formed in an ice bath. 
Postupak dobivanja dermalnog matriksa (10) u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku dodavanja laminina u otopinu kolagena (112) uzimanjem 2,5 ml pripravljene otopine kolagena, dodavanju tome 20 ml laminina, te njihovom miješanju u ledenoj kupelji.
The method of claim 1, wherein the cytotoxic agent is selected from the group consisting of a toxin, a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme. 
Imunokonjugat, naznačen time, da obuhvaća protutijelo prema bilo kojem od zahtjeva 1 do 7, kovalentno priključeno na sljedeće: citotoksično sredstvo, opcijski kemoterapeutsko sredstvo, dio molekule lijeka, antibiotik, radioaktivni izotop i nukleolitički enzim;
A salt according to any one of the preceding claims, wherein the amine containing one or more hydroxyl and/or carboxylic groups is selected from the group consisting of L-arginine, deanol, diethanolamine, diethylethanolamine, ethanolamine, meglumine, 2-morpholine ethanol, 1-(2-hydroxyethyl)-pyrrolidine, triethanolamine and tromethamine. 
Sol prema jednom od prethodnih zahtjeva, naznačena time, što je amin odabran iz grupe koju čine L-arginin, deanol, dietanolamin, dietiletanolamin, etanolamin, meglumin, 2-morfolin etanol, 1-(2-hidroksietil)-pirolidin, trietanolamin i trometamin, poželjno iz grupe koju čine L-arginin, dietanolamin, meglumin, trietanolamin i trometamin.
The device according to anyone of claims 2-3, wherein the aqueous solution has a pH from 6 to 8. 
Uređaj sukladno patentnom zahtjevu 2, pri čemu koncentracija kolistimetat natrij u rasponu od 80 do 120 mg A/mL.
Another preferred composition of the invention comprises: 
Datum podnošenja europske prijave patenta:
contacting the antigen presenting cell of step (iii) with a T cell to evaluate the ability of the peptide to simulate the T cell; and 
(1v) stavljanja u kontakt sa stanicama koje prezentiraju antigen iz koraka (iii) s T-stanice kako bi se procijenila sposobnost peptida da stimulira T-stanice; i
The inner part 60 has indentations 74, which the legs 75 of the U-shaped metal parts may grip into when clicking them onto there. 
Unutarnji dio 60 ima nazubljenja 74, u koje se mogu zahvatiti krakovi 75 metalnih dijelova koji imaju U-oblik, kada se ovi skočno pritisnu na njih.
a control unit in said base body comprising a microprocessor or micro-controller; 
- < kontrolnu jedinicu (5) u navedenom osnovnom tijelu (1) koja sadrži mikroprocesor ili mikrokontroler;
The Compound of Claim 3 where R6 is heteroaryl optionally substituted with 1, 2, or 3 R9 groups; or a single stereoisomer or mixture of stereoisomers thereof and optionally as a pharmaceutically acceptable salt or solvate thereof. 
Spoj prema patentnom zahtjevu 3, naznačen time što je R6 jednako heteroaril izborno supstituiran sa 1, 2 ili 3 R9 grupe; ili njegov pojedinačni stereoizomer ili smjesa stereoizomera i izborno kao njegova farmaceutski prihvatljiva sol ili solvat.
a high frequency adjusting step in which the speech decoding device adjusts the high frequency component generated in the high frequency generating step to generate an adjusted high frequency component; a low frequency temporal envelope analysis step in which the speech decoding device obtains temporal envelope information by analyzing the low frequency component transformed into the frequency domain in the frequency transform step, wherein the temporal envelope information is obtained by obtaining power of each QMF subband sample of the low frequency component transformed into the frequency domain in the frequency transform step; 
koraku primarnog podešavanja visoke frekvencije, u kojem naprava za dekodiranje govora obrađuje visokofrekventnu komponentu generiranu u koraku generiranja visoke frekvencije, gdje dio postupka uključuje podešavanje pojačanja, dodavanje buke, te dodavanje sinusoida kako bi se generiralo izlazni signal; koraku analiziranja nisofrekventne vremenske ovojnice, u kojem naprava za dekodiranje govora dobiva informacije o vremenskoj ovojnici analiziranjem niskofrekventne komponente pretvorene u frekventno područje u koraku pretvorbe frekvencije;
The piece of fitness equipment according to claim 9, wherein the wearable holder includes a first layer and a second layer made of a textile material. 
Fitnes uređaj prema zahtjevu 7, naznačen time da su prvi sloj (32a) i drugi sloj (33a) izrađemi od tekstilnog materijala.
A conjugate comprising the anti-CLDN6 antibody of claim 1 coupled to a therapeutic agent, preferably a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji se sastoji od antitijela suglasno bilo kojem zahtjevu 1-11, povezanog sa nekim terapeutskim agensom, poželjno toksinom ili radioizotopom, lijekom ili nekim citotoksičnim agensom.
A typical regimen may involve administration once/day for five days every three weeks. 
Tipičan režim može uključiti davanje jednom/dan za pet dana svaka tri tjedna.
attachment of a terminal fixing element (10) to the settlement profile (1) by pressure or sliding into the groove (3); 
- pričvršćivanje krajnjeg elementa za pričvršćivanje (10) na ugradbeni profil (1) pomoću pritiska ili klizanjem u utor (3);
is hydrogen or C14-alkyl; or a pharmaceutically acceptable acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
R> je vodik ili C,,-alkil; ili njegova farmaceutski prihvatljiva kiselinska adicijska sol, racemična smjesa, ili njegov odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
a layer containing a nitrite; and 
(1) sloj koji sadrži nitrit; 1
Exponentially growing CHO-WBL cells were seeded in McCoy's 5A medium supplemented with 10% fetal-bovine serum, L-glutamine (2 mM), penicillin G (100 units/ml), and streptomycin (100 g/ml) at approximately 0.5×106 cells/25 cm2 flask. 
Stanice CHO-WBL sa eksponencijalnim rastom su zasijane u McCoy's SA podlozi dopunjenoj sa 10% fetusnim goveđim serumom, L-glutaminom (2 mM), penicilinom G (100 jedinica/ml), i streptomicinom (100 ug/ml) u približno 0.5 x 10* stanica /25 em? bočice.
and their salts, solvates, N- oxides and the salts and solvates thereof. 
i njihove soli, solvati, N-oksidi, te njihove soli i solvati.
optionally mixing the granules of step (3) with the remaining excipients in a mixer to obtain the final mixture; 
(4) po želji miješanje granula iz koraka (3) s preostalim pomoćnim sredstvima u mješalici da bi se dobila konačna mješavina;
A monoclonal antibody binding to human CD38, wherein said antibody comprises human light chain and human heavy chain variable regions, wherein the light chain variable region comprises a VL CDR1 having the sequence as set forth in SEQ ID No:13, a VL CDR2 having the sequence as set forth in SEQ ID No:14 and a VL CDR3 having the sequence as set forth in SEQ ID No:15, and the heavy chain variable region comprises a VH CDR1 having the sequence as set forth in SEQ ID No:18, a VH CDR2 having the sequence as set forth in SEQ ID No:19 and a VH CDR3 having the sequence as set forth in SEQ ID No:20. 
Monoklonsko protutijelo koje se vezuje za humani CD38, pri čemu navedeno protutijelo sadrži humani laki lanac i varijabilne regije humanog teškog lanca, pri čemu varijabilna regija lakog lanca sadrži VL CDR1 koji ima slijed naveden u SEQ ID No: 13, VL CDR2 koji ima slijed naveden u SEQ ID br: 14 i VL CDR3 koji ima slijed naveden u SEQ ID br: 15, a varijabilno područje teškog lanca sadrži VH CDR1 koji ima slijed kao što je navedeno u SEQ ID br: 18, VH CDR2 koji ima slijed naveden u SEQ ID br:19 i VH CDR3 koji ima slijed kako je navedeno u SEQ ID br:20.
The alcoholic beverage of claim 1, wherein at least 5 mole percent of the ethanol is a deuterated alcohol having the formula or or or the formula CD3CD2OH. 
Alkoholno piće prema patentnom zahtjevu 1, u kome najmanje 5 molarnih postotaka etanola predstavlja deuterirani alkohol koji ima formulu ili ili ili formulu CD2CD;OH.
The method of claim 15, wherein said individual is a mammal selected from the group consisting of: domestic mammals, rodents, and humans. The method of claim 16, wherein said individual is a human. A method for killing or inhibiting the proliferation or growth of a tumor cell, comprising contacting said tumor cell with a compound of claim 1 or a salt form thereof. 
Postupak ubijanja ili inhibicije proliferacije ili rasta tumorskih stanica, koji obuhvaća dovođenje u doticaj tumorske stanice sa spojem prema zahtjevu 1 ili njegovim oblikom soli, pri čemu se in vitro ta tumorska stanica izlaže spoju ili njegovoj soli, posebno kada je tumorska stanica maligna stanica pojedinca.
The process according to any one of the preceding claims, characterized in that the final solids content of the aqueous suspension after step d) is at least 1 wt%, preferably at least 2 wt%, more preferably at least 3 wt% higher than the initial solids content of the aqueous suspension obtained in step b). 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je konačni udio krutih tvari u vodenoj suspenziji nakon koraka d) najmanje 1 % tež., poželjno najmanje 2 % tež., poželjnije najmanje 3 % tež. veći nego početni udio krutih tvari u vodenoj suspenziji dobivenoj u koraku b).
Porcine reproductive and respiratory syndrome virus resistant animals 
ŽIVOTINJE OTPORNE NA VIRUS REPRODUKTIVNOG I RESPIRATORNOG SINDROMA SVINJA
In fig. 8a-c the base unit 3 is shown without the collapsible container 2 attached, to allow a better view of the internal parts of the base unit 3. 
Na slikama 8a-c osnovni dio 3 je prikazan bez priključenog sklopivog spremnika 2, da se bolje vide unutarnji dijelovi osnovne jedinice 3.
The upper portion of Figure 1 provides an end or front view, showing an optional control for an anchor winch. 
Gornji dio Slike 1 prikazuje stražnji ili prednji pogled, koji prikazuje opcionalnu kontrolu za sidreno vitlo.
A compound of the formula 
spoj s formulom (II) [image] gdje
The cladding assembly of claim 1, wherein the core element carries the first attachment formation and the cladding element carries the second attachment formation. 
Sklop obloge prema zahtjevu 1, gdje osnovni element (2) nosi prvi pričvrsni oblik, a obložni element (7) nosi drugi pričvrsni oblik.
The polymeric device material of claim 1 wherein the amount of hydrophilic side-chain macroner in the composition is 2 to 4% (w/w). 
Polimerni materijal za navedeni uređaj u skladu s patentnim zahtjevom 10, naznačen time što količina hidrofilnog pobočnog makromera je 2 do 4 % (težinski).
mixtures of pH-dependent polymer and a water insoluble, pH-independent polymer such as ethylcellulose or ethyl acrylate methyl methacrylate copolymer (NE30D). 
smjese pH-ovisnih polimera i u vodi netopljivih, pH-neovisnih polimera kao što je etilceluloza ili kopolimer etil akrilat metil metakrilata (NE30D).
The conjugate according to claim 14, wherein the compound-linker molecule has a structure represented by the following formula: wherein Ab represents the human monoclonal anti-mesothelin antibody 6A4 having the heavy chain variable region sequence: and the light variable region sequence: 
Tvar konjugat u skladu s patentnim zahtjevom 14, pri čemu tvar molekule poveznika ima strukturu predstavljenu sljedećom formulom: [image] gdje Ab predstavlja ljudsko monoklonsko anti-mezotelijsko protutijelo 6A4 koje ima slijed varijabilne regije teškog lanca:
A method for obtaining stem cells comprising 
Postupak za dobivanje Lgr5+ matičnih stanica naznačen time da sadrži
A compound according to claim 4 in crystalline form which is characterised by an X-ray powder diffraction pattern as shown in Figure 2. 
Spoj prema zahtjevu 4 u kristalnom obliku koji je naznačen time da ima uzorak difrakcije X-zraka na prahu kako je prikazano na Slici 2.
9) indicate that rats treated with rapamycin displayed significantly increased levels of cholesterol relative to a vehicle control group, while cholesterol levels in the 42-O-(D-fructosylcarbonyl)rapamycin group were significantly lower (p<0.01) than in the rapamycin group and not significantly different than the vehicle. 
Rezultati (slika 9) pokazuju da štakori tretirani rapamicinom pokazuju značajno povišene razine kolesterola u usporedbi s kontrolnom grupom, dok su razine kolesterola u grupi 42-O-(D-fruktozilkarbonil)rapamicina bile značajno niže (p < 0,01) nego u rapamicinskoj grupi, a ne značajno različite od nosača.
The receiver of claim 7, wherein a size of a field for the PSI/SI reprocessing information is one bit. 
Prijamnik iz patentnog zahtjeva 7, gdje je veličina polja za ponovnu obradu PSU/SI informacija jedan bit.
The compound or salt for use according to claim 16, wherein said myeloproliferative disorder is chronic myelomonocytic leukemia (CMML). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj kronična mijelomonocitna leukemija (CMML).
The method of claim 28, wherein the eukaryotic cells are selected from the group consisting of Chinese hamster ovary (CHO) cells, COS cells, BHK cells, myeloma cells, NIH 3T3, fibroblasts and immortalised human cells. The method of claim 28, wherein the host cell expresses a recombinant transactivator, capable of transactivating the promoter coding for expression of the polyclonal protein. 
NSO, YB2/0), stanice NIH 3T3, fibroblasti ili imortalizirane ljudske stanice, poput stanica HeLa, stanice HEK293 ili stanica PER.C6. . Postupak u skladu s patentnim zahtjevom 11, naznačen time što stanica-domaćin eksprimira rekombinantni transaktivator, koji može transaktivirati promotor koji kodira ekspresiju poliklonskog proteina,
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
The solid pharmaceutical composition of claim 1, which is substantially free of lubricant. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1, koja ne sadrži lubrikant.
Q represents an oxygen atom or RaN, wherein Ra represents a hydrogen atom or a C1-C6 alkyl group; 
Q predstavlja atom kisika ili R*N, gdje R* predstavlja atom vodika ili C;-Ce alkil grupu;
Drying at reduced pressure, yields 0.58 g of a white solid corresponding to the 2-thioisosorbide 5-mononitrate disulfide product of interest (2). 
Sušenjem pod smanjenim tlakom dobije se 0,58 g bijele krute tvari koja odgovara željenom proizvođu 2-tioizosorbid 5-mononitrat disulfidu (2). Iskorištenje:
A binding moiety which binds to a conformational epitope formed by amino acid sequences NDETCEQRA (SEQ ID NO: 2) and SHKDMQL (SEQ ID NO: 3) of C5a, wherein the binding moiety binds to at least one amino acid within the amino acid sequence according to SEQ ID NO: 2 and to at least one amino acid within the amino acid sequence according to SEQ ID NO: 3; 
C5a protutijelo ili njegov fragment koji veže antigen sukladno bilo kojem od patentnih zahtjeva 1 do 4, pri čemu se protutijelo ili njegov fragment koji veže antigen veže s konformacijskim epitopom formiranim sekvencama aminokiseline NDETCEQRA (SEQ ID NO: 2) i SHKDMQL (SEQ ID NO: 3) od C5a, pri čemu se protutijelo ili njegov fragment koji veže antigen veže s najmanje jednom aminokiselinom unutar sekvence aminokiseline sa SEQ ID NO: 2 i s najmanje jednom aminokiselinom unutar sekvence aminokiseline sa SEQ ID NO: 3;
(LU-D) is a Linker unit-Drug unit moiety, wherein: 
(LU-D) je skupina jedinica poveznice-jedinica lijeka, pri čemu:
The process of claim 1, further comprising a step of dry coating the coated core particles with a hydrophobic silica having a median particle size in a range of from 20 nm to 500 nm. 
Postupak sukladno zahtjevu 1, naznačeno time, da se nadalje sastoji od koraka u kojem se obložene čestice jezgre oblažu hidrofobnim silicijevim-dioksidom.
The liquefied gas treatment system according to claim 7, wherein the boil-off gas supplied to the heat exchanger is a boil-off gas compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se treću struju dodatno komprimira u drugom kompresoru (13b) i šalje u izmjenjivač topline (21).
Another object of the present invention is to provide a sheet in which two portions thereof can be heat-sealed to each other, allowing to produce packages and containers that are sealed and are therefore also hermetic. 
Drugi cilj predloženog izuma je osigurati foliju u kojoj se njezina dva dijela mogu međusobno toplinski zavariti, da se omogući izradu pakiranja i spremnika koji su zavareni i stoga su također hermetički.
Moreover, the present invention provides a shoe with breathable and waterproof sole and upper that is structurally simple to obtain. 
Štoviše, predmetni izum omogućuje cipelu s prozračnim i vodootpornim potplatom i gornjištem jednostavne konstrukcije i postupka proizvodnje.
Here, the sidechain of Formula 36, (38 g, 99.6 mmol) was dissolved in toluene to a known concentration (0.09524 g/mL). 
Ovdje je bočni lanac formule 36 (38 g, 99.6 mmol) bio otopljen u toluenu do poznate koncentracije (0.09524 g/mL).
This assay measures the ability of a test compound to inhibit the growth of a BT-474 tumour cell xenograft (human mammary carcinoma obtained from Dr Baselga, Laboratorio Recerca Oncologica, Pasco Vall D'Hebron 119-129, Barcelona 08035, Spain) in Female Swiss athymic mice (Alderley Park, nu/nu genotype) (Baselga, J. et al. 
Ovim testom mjeri se sposobnost ispitivanog spoja da inhibira rast ksenografta BT-474 tumorskih stanica (humani karcinom dobiven od Dr Baselga, Laboratorio Recerca Oncologica, Paseo Vall D'Hebron 119-129, Barcelona 08035, Å panjolska) u atimusnim miševima Female Swiss (Baselga, J. i sur.
A compound according to 43 wherein R1 is a mono-chlorophenyl or dichlorophenyl group. 
Spoj prema zahtjevu 37, naznačen time što je R' mono-klorofenil ili diklorofenil skupina.
As further examples, embodiments of this synthesis are provided by the synthesis process described herein when R2i is one of H, C1-10alkyl (linear or branched), —CH2aryl, —S(O)2aryl, and —S(O)2C1-6alkyl. 
R»' je jedan od C,.oalkila, -CHoarila, -S(O)arila, i -S(O),C,.salkila, gdje je navedeni C,.qoalkil ostatak linearan ili razgranat, i navedeni Crggalkil 1 navedeni aril ostaci su opcionalno supstituirani s najmanje jednim .
Method according to claim 12 or 13, characterised in that it makes use of a device according to any one of the claims 1 to 7 or a floating structure according to any one of the claims 7 to 11. 
Postupak sukladno zahtjevu 12 ili 13, naznačen time što upotrebljava uređaj sukladno bilo kojem od zahtjeva 1 do 7 1li plutajuće strukture sukladno bilo kojem od zahtjeva 7 do 11.
A dressing according to any one of claims 1 or 2, wherein the semi-solid pliable sheet comprises a mixture of the super-absorbent polymer fibre and a cellulose fibre in a non-layered structure. 
Obloga u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačena time, da se polukruti savitljivi list sastoji od mješavine super-upijajućeg polimernog vlakna 1 celuloznog vlakna u neslojevitoj strukturi.
The compound of claim 1, characterized by the structure of formula VII: 
VI 3. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom VII:
A layer comprising a polar thermoplastic polymer applied over and to the adhesive layer (ii), said polar thermoplastic polymer being selected from a polyurethane or a polyolefin grafted with polar groups; 
(ili) sloj koji sadrži polarni termoplastični polimer, kojeg se primjenjuje preko i na sloj ljepila (ii);
at least one of such parts of fabric consists of a portion of knitted tubular fabric (1) made by means of a circular knitting machine for hosiery or by means of knitting machine for knitwear; 
postavljanje cjevaste pletene tkanine (1) koja je proizvedena pomoću stroja za kružno pletenje za čarape ili pomoću stroja za pletenje za pletenu odjeću, ili proizvodnju pletene cjevaste tkanine (1) pomoću stroja za kružno pletenje za čarape ili pomoću stroja za pletenje za pletenu odjeću;
The pharmaceutical composition of any one of the preceding claims, wherein the ratio of the first lipid nanoparticle to the second lipid nanoparticle in the pharmaceutical composition is about 1:1, about 2:1, about 3:1, or about 4:1. 
Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da omjer prve lipidne nanočestice i druge lipidne nanočestice u farmaceutskom pripravku iznosi približno 1:1, približno 2:1, približno 3:1 ili približno 4:1.
There is also provided in accordance with some embodiments an agent for use in the case of fructose intolerance, which contains glucose isomerase. 
Glukoza izomeraze za uporabu u skladu sa zahtjevom 4, naznačena time, što crijevna intolerancija fruktoze je uzrokovana poremećajem absorpcije fruktoze.
Dextran sulfate, or said pharmaceutically acceptable derivative thereof, for use according to any of the claims to 1 to 4, wherein said average molecular weight is within a range of 2 000 and 10 000 Da, preferably within a range of 3 000 and 10 000 Da, and more preferably within a range of 3 500 and 9 500 Da, such as within a range of 4 500 and 7 500 Da, or within a range of 4 500 and 5 500 Da. 
Dekstran sulfat ili njegov navedeni farmaceutski prihvatljiv derivat, za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što je navedena prosječna molekularna masa unutar raspona od 2000 i 10000 Da, poželjno unutar raspona od 3000 i 10000 Da, i poželjnije unutar raspona od 3500 i 9500 Da, kao što je unutar raspona od 4500 i 7500 Da, ili unutar raspona od 4500 i 5500 Da.
In one embodiment, each —RB2, where present, is independently selected from: 
-W* je neovisno -H ili -W"; gdje -W" je neovisno odabran od:
This will include vital signs (blood pressures, pulse rate, respiratory rate and temperature), pulse oximetry, physical examination, ECG, laboratory tests (hematology, serum chemistry, liver function tests, and urinalysis) and pharmacokinectic blood sampling. A pharmaceutical composition for use in the treatment of depression, alcohol addiction and/or dependence, premenstrual tension, premenstrual syndrome or premenstrual dysphoric disorder, comprising 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 12 h to 24 h following administration. 
Farmaceutski sastav za uporabu u liječenju depresije, bolesne potrebe za alkoholom i/ili ovisnosti o alkoholu, predmenstrualne napetosti, predmenstrualnog sindroma ili predmenstrualnog disforičnog poremećaja, naznačen time, da sadrži 3a-hidroksi-3f-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata, kod čega sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 5ng/ml do 500 ng/ml u trajanju od 12 h do 24 h nakon davanja.
The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein X is CR4. 
Farmaceutski sastav prema zahtjevu 1 ili 2, pri čemu X je N.